Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Medclair ABNGM:MCLR 71 Equity-to-Asset is 0.89 as of Mar. 2026, which is 6% above its 10-year median of 0.84. GuruFocus rates NGM:MCLR with a GF Score™ of 71/100 and a GF Value™ of kr2.39 (Modestly Overvalued). Among 851 Medical Devices & Instruments companies, Medclair AB ranks better than 91.66% on this metric.
Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Medclair AB's Total Stockholders Equity for the quarter that ended in Mar. 2026 was kr79.17 Mil. Medclair AB's Total Assets for the quarter that ended in Mar. 2026 was kr89.49 Mil.
Therefore, Medclair AB's Equity to Asset Ratio for the quarter that ended in Mar. 2026 was 0.89.
The historical rank and industry rank for Medclair AB's Equity-to-Asset or its related term are showing as below:
NGM:MCLR'
s Equity-to-Asset Range Over the Past 10 Years
Min: 0.1 Med: 0.84 Max: 0.91
Current: 0.89
During the past 11 years, the highest Equity to Asset Ratio of Medclair AB was 0.91. The lowest was 0.10. And the median was 0.84.
NGM:MCLR's Equity-to-Asset is ranked better than 91.66% of 851
companies
in the Medical Devices & Instruments industry
Industry Median: 0.64
vs NGM:MCLR: 0.89
Medclair AB (NGM:MCLR) Equity-to-Asset Explanation
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Medclair AB Equity-to-Asset Related Terms
Medclair AB Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for Medclair AB's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NGM:MCLR vs ABT, SYK, MDT: Equity-to-Asset Comparison
For the Medical Devices subindustry, Medclair AB's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medclair AB Equity-to-Asset vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Medclair AB's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Medclair AB's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Medclair AB's Equity to Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Medclair AB (NGM:MCLR) has a Equity-to-Asset of 0.89 as of Mar. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Medclair AB and its competitors. This is near median its historical median of 0.84. Over the past decade, Medclair AB's Equity-to-Asset has ranged from 0.10 to 0.91. According to the industry distribution chart, Medclair AB ranks #71 out of 851 companies in the Medical Devices & Instruments industry, placing it in the top 8.3%.
Is Medclair AB's Equity-to-Asset too high?
Medclair AB's current Equity-to-Asset of 0.89 is near median its 10-year median of 0.84. Over the past 10 years, this metric has ranged from a low of 0.10 to a high of 0.91. The Medical Devices & Instruments industry median Equity-to-Asset is 0.64. Medclair AB's value of 0.89 is 39.1% above this industry median. Based on the distribution chart, Medclair AB ranks #71 out of 851 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Medclair AB has a GF Score™ of 71/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Medclair AB's Equity-to-Asset compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Medclair AB ranks #71 out of 851 companies for Equity-to-Asset. This places Medclair AB in the top 8% of its industry — outperforming the majority of peers. The industry median Equity-to-Asset is 0.64. Medclair AB's value of 0.89 is 39.1% above this benchmark. Historically, Medclair AB's own Equity-to-Asset has ranged from 0.10 to 0.91 over the past decade. While the company's 10-year median is 0.84 vs. the industry median of 0.64, Medclair AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Medical Devices & Instruments company?
The median Equity-to-Asset among Medical Devices & Instruments companies is 0.64, based on 851 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Medclair AB's current Equity-to-Asset of 0.89 is 39.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Medclair AB and its competitors. For the Medical Devices & Instruments industry, the median Equity-to-Asset is 0.64 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Medclair AB's current Equity-to-Asset is 0.89, which is near median its own 10-year median of 0.84. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medclair AB stock overvalued right now?
Based on GuruFocus' analysis, Medclair AB (NGM:MCLR) is currently considered Modestly Overvalued. The stock's GF Value™ is kr2.39, compared to a current price of kr2.89 — trading 20.9% above its estimated fair value. The current Equity-to-Asset is 0.89, which is near median its 10-year median of 0.84 and 39.1% above the Medical Devices & Instruments industry median of 0.64. Medclair AB's overall GF Score™ is 71/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Medclair AB (NGM:MCLR), the current Equity-to-Asset is 0.89 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Medclair AB (NGM:MCLR) Overvalued in 2026?
Based on GuruFocus' analysis, Medclair AB stock appears to be overvalued.
The current stock price of kr2.89 is trading 20.9% above its estimated GF Value™ of kr2.39.
GuruFocus considers Medclair AB to be Modestly Overvalued.
Key valuation signals for NGM:MCLR:
Equity-to-Asset: 0.89 (near median its 10-year median of 0.84)
GF Value™: kr2.39 vs. price of kr2.89 (20.9% above fair value)
Industry Position: 39.1% above the Medical Devices & Instruments median (#71 of 851)
No single metric tells the full story. See the NGM:MCLR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Medclair AB operates in healthcare industry. The company has two units: Central Destruction Unit (CDU) and Mobile Destruction Unit (MDU) decomposes the nitrous oxide entering the unit, transforming it to nitrogen (N2) och oxygen (O2). It also provide solutions for various N2O methods such as double mask, single mask, mouthpiece, or free flow, which ensures a safe work environment for healthcare professionals.
71GF Score
Get the complete analysis for NGM:MCLR
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NGM:MCLR has been successfully added to your 
